Xenon Pharmaceuticals (XENE) Accumulated Depreciation (2021 - 2025)

Xenon Pharmaceuticals (XENE) has 5 years of Accumulated Depreciation data on file, last reported at $15.4 million in Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $15.4 million, up 14.74% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.4 million (up 14.74% YoY), and the FY2025 annual result was $15.4 million, up 14.74% from the prior year.
• Accumulated Depreciation climbed to $15.4 million in Q4 2025 per XENE's latest filing, from $13.5 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $15.4 million in Q4 2025 and troughed at $8.7 million in Q4 2022.
• A 5-year average of $12.4 million and a median of $13.4 million in 2021 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation tumbled 34.79% in 2022, then climbed 29.25% in 2023.
• A 5-year view of Accumulated Depreciation shows it stood at $13.4 million in 2021, then plunged by 34.79% to $8.7 million in 2022, then rose by 29.25% to $11.3 million in 2023, then climbed by 19.67% to $13.5 million in 2024, then increased by 14.74% to $15.4 million in 2025.
• Business Quant data shows XENE's Accumulated Depreciation at $15.4 million in Q4 2025, $13.5 million in Q4 2024, and $11.3 million in Q4 2023.